Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.80 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310847 | 0.89 | SYK (0.82) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL2627398 | 0.89 | SYK (1.00) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL3271846 | 0.89 | SYK (0.82) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL6310843 | 0.89 | SYK (0.82) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL3582905 | 0.89 | SYK (0.82) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL2627375 | 0.89 | SYK (0.82) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL6310853 | 0.89 | SYK (0.82) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL14360841 | 0.88 | SYK (0.67) | SYKATMCTRB1MAPTCTSS | |
| SCHEMBL20674340 | 0.88 | SYK (0.80) | SYKATMCTRB1CTSKMAPT | |
| SCHEMBL10936907 | 0.88 | SYK (0.80) | SYKATMCTRB1CTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-1330436-B1 | N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR3-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7034042-B2 | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as CCR33 receptor antagonists | NOVARTIS AG (CH) | 2006-04-25 | — | — | US | disclosed |
| US-20040087621-A1 | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| EP-1330436-A1 | N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR3-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030898-A1 | N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR33 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | SYK 3212/4885ATM 4624/4885CTRB1 340/4885 |
| US-20040087621-A1 | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists | CCR1, CCR3, CCR8 | SYK 4125/4885ATM 4042/4885CTRB1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.